Have Bambusa Therapeutics insiders bought shares recently?

Yes. Insiders of Bambusa Therapeutics (BBTX) filed 6 open-market purchases in the last 90 days; the latest was filed on Nov 3, 2026.

How often do Bambusa Therapeutics insiders buy and sell shares?

Since 2026, Bambusa Therapeutics insiders reported 6 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2026.

Who is selling Bambusa Therapeutics stock?

No open-market sale by an insider of Bambusa Therapeutics (BBTX) was filed with the SEC in the last 90 days.

Do members of Congress trade BBTX?

No trade in Bambusa Therapeutics (BBTX) was disclosed by a member of Congress in the last 12 months.

Where does this data come from?

From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.

Bambusa Therapeutics (BBTX) insider trading and stock trades

OQRO

Ask OQRO about this page

Ask

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at BBTX buy and sell in the last 90 days?Which members of Congress and which funds traded BBTX recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

Insider open-market trades, filed in the last 90 days6 buys · 0 sales~$58.6M boughtInsider trades →Congress trades, disclosed in the last 90 daysNoneNo House or Senate report names this stockCongress →Fund 13F changes, last 12 monthsNoneNo followed fund reported a changeFund moves →Federal contracts starting in the last 12 monthsNoneNo award found for this companyContracts →

Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.

Biological Products, (No Diagnostic Substances) company based in Boston, MA. Listed, but no annual report (10-K) filed yet under this SEC registration.

Last 12 months

Not enough history

Market value

–

No annual report yet, so no share count

On the public record for Bambusa Therapeutics over the 12 months to Nov 14, 2026: 2 clinical trials.

Last 30 days

Written by software from the filings listed below · Nov 13, 2026

Insiders. In the 30 days to Nov 13, 2026, insiders filed 6 open-market purchases (about $58.6M, in 3 filings, by 3 people) and 0 open-market sales. Bambusa Therapeutics on OQRO

3 more points, with the facts they come from, are in OQRO Pro.

Insider buying and selling since 2026

Insiders of Bambusa Therapeutics reported 6 open-market purchases and 0 sales since 2026; purchases in 2026.

Year	Bought	Sold
2026	$58.6M6×6 trades	—

Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.

Holders above 5%

Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.

Late-stage clinical trials

0 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps (crswnp). The ones with the nearest registered primary completion date still ahead:

Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.

H-1B filings

Department of Labor

1 certified in FY2026 Q3, vs 0 a year earlier. 1 position in total, median offered wage $92K a year.

Program Manager · 1

Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.

Latest

See everything

Fund moves

13D stake

14.6%Stake

Filed 8d ago

A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.

More Official record

Fund moves

Want the short version?

Bambusa Therapeutics

How this filing works

Questions about Bambusa Therapeutics insider trading

Bambusa Therapeutics is in 1 disclosure basket

Insiders who traded Bambusa Therapeutics

Other Biological Products, (No Diagnostic Substances) companies

Last 30 days

Insider buying and selling since 2026

Holders above 5%

Late-stage clinical trials

H-1B filings

Latest

14.6%Stake

9.2%Stake · was 9.2%

~$44Macross 3 transactionsin 1 filing

H-1B filings

Last 30 days

Holders above 5%

Late-stage clinical trials

Insider buying and selling since 2026